KDJ63102
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CNTO-1959, CAS: 1350289-85-8
Safety of guselkumab and ustekinumab treatment in patients with moderate-to-severe plaque psoriasis combined with latent tuberculosis or inactive hepatitis B virus infection: A retrospective multicenter observational study., PMID:40482822
Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey., PMID:40476147
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease., PMID:40470513
Comparative Efficacy of Different Targeted Therapies in Patients With Moderate-to-Severe Ulcerative Colitis: Systematic Review/Network Meta-Analysis and Mechanistic Overview., PMID:40468857
Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study., PMID:40468568
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations., PMID:40465057
Commentary: Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40463376
Guselkumab (Tremfya) - an IL-23 antagonist for Crohn's disease., PMID:40459404
The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris., PMID:40455345
A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks., PMID:40450642
Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors., PMID:40439875
Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study., PMID:40439435
Comparative Efficacy of Ustekinumab and Guselkumab in Improving Itch in Severe Psoriasis Patients., PMID:40432363
Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors., PMID:40429269
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis., PMID:40407729
Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany., PMID:40402376
Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Cohort., PMID:40402160
Early-Stage Limited Cutaneous Systemic Sclerosis Successfully Treated With Guselkumab: Possibility of Early Intervention in the Pathogenesis., PMID:40401802
Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe., PMID:40396610
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?, PMID:40394835
Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry., PMID:40387427
A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment., PMID:40383754
Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement-Monocentric Real-World Evidence., PMID:40364181
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease., PMID:40357993
Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis., PMID:40329054
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis., PMID:40327280
Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease., PMID:40324965
Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study., PMID:40319105
Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis., PMID:40299379
EBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis., PMID:40297411
Effectiveness and Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis in Real-World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study., PMID:40293170
Efficacy and Safety of IL-17 and IL-23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real-World Study., PMID:40285439
New Interleukin-23 Antagonists' Use in Crohn's Disease., PMID:40283885
The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials., PMID:40268126
Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort., PMID:40264783
Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables., PMID:40263185
Guselkumab: a safe treatment option for patients with comorbid psoriasis and multiple sclerosis., PMID:40248968
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study., PMID:40238960
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study., PMID:40238056
Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study., PMID:40237394
Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis., PMID:40227059
Roflumilast Cream 0.3% for a Patient With Genital Psoriasis Refractory to Other Topical and Systemic Treatments: A Case Report., PMID:40212438
Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials., PMID:40209685
Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers., PMID:40176606
Successful Guselkumab Treatment in a Patient with Comorbid Psoriasis and Amyotrophic Lateral Sclerosis: A Case Study and Literature Review., PMID:40166719
A Practical Guide to the Use of Guselkumab for Moderate-Severe Ulcerative Colitis., PMID:40162667
Comparative efficacy of pharmacologic interventions in ulcerative colitis: a network meta analysis., PMID:40156676
Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in Japan., PMID:40156259
Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40145093
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study., PMID:40113101
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
